

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
07/565,673	08/10/1990	JOHANNES C. VAN DER LAAN		8222
7590 10/11/2006			EXAMINER	
DEBRA J. GLAISTER PATENT AGENT			FRONDA, CHRISTIAN L	
GENENCOR INTERNATIONAL INC. 925 PAGE MILL ROAD PALO ALTO, CA 94304			ART UNIT	PAPER NUMBER
			1652	<u>-</u> .
		DATE MAILED: 10/11/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.



	Application No.	Applicant(s)				
Office Action Occurred	07/565,673	VAN DER LAAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Christian L. Fronda	1652				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 06 Ju	ly 2006.					
	_ _					
,	,—					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>50,53 and 54</u> is/are pending in the app	olication					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>50,53 and 54</u> is/are rejected.						
7) Claim(s) is/are objected to.						
<u> </u>						
,— , , <u>——</u> .	cicolion requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on 10 August 1990 is/are:	•	-				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) ☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priori	3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Dat	te				
B) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5)	itent Application				
0) Utilet						

Application/Control Number: 07/565,673 Page 2

Art Unit: 1652

DETAILED ACTION

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/06/2006 has been entered.
- 2. Claims 48, 50, 53, and 54 are pending and under consideration in this Office Action.
- 3. The rejection of claims 48, 50, 53, and 54 under 35 U.S.C. 112, second paragraph, as being indefinite has been withdrawn in view of applicants' extensive claim amendments and arguments filed on 02/06/2006.

Claim Rejections - 35 U.S.C. § 112, 1st Paragraph

- 4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

 The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 5. Claims 50, 53, and 54 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicants' arguments filed 07/06/2006 have been acknowledged but are not persuasive.

As stated in the previous Office Action, gene elements which are not particularly described including the promoter, regulatory elements, and 5' and 3' flanking non-coding regions are essential to the function of the claimed invention since the claims recite a gene encoding a Bacillus wild-type alkaline serine protease. Therefore, the structure of these gene elements which applicants considers as being essential to the function of the claim are not conventional in

Art Unit: 1652

the art. There is no known or disclosed correlation between the coding region of the wild-type alkaline serine protease and the structure of the non-described promoter, regulatory elements, and 5' and 3' flanking non-coding regions of the gene. There is no additional disclosure of physical and/or chemical properties of these gene elements. In particular there is no disclosure of the nucleotide sequence and structure of the promoter, regulatory elements, and 5' and 3' flanking non-coding regions.

In view of the above considerations, one of skill in the art would not recognize that applicants were in possession of the gene elements including promoter, regulatory elements, and 5' and 3' flanking non-coding regions of the Bacillus wild-type alkaline serine protease.

Amending the claim to recite the plasmid expression vector or integration cassette comprising a polynucleotide encoding the recited mutant high alkaline serine protease may overcome the rejection.

Conclusion

- 6. No claim is allowed.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.
- 8. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CLF

TEKCHÁND SAIDHÁ PRIMARY EXAMINER